(0.15%) 5 078.16 points
(0.04%) 38 521 points
(0.32%) 15 747 points
(-0.80%) $82.69
(-5.79%) $1.707
(-0.26%) $2 336.10
(-0.32%) $27.28
(-0.85%) $915.00
(0.09%) $0.935
(0.66%) $10.98
(0.01%) $0.803
(-0.98%) $92.27
Quarter results today
(bmo 2024-04-24)
Expected move: +/- 0.00%
Live Chart Being Loaded With Signals
Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. The company's lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy...
Stats | |
---|---|
Today's Volume | 3 104.00 |
Average Volume | 44 945.00 |
Market Cap | 28.43M |
EPS | $0 ( 2023-12-15 ) |
Next earnings date | ( $0 ) 2024-06-07 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -5.42 |
ATR14 | $0.108 (2.98%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2022-12-09 | Goodman Gerald | Buy | 20 000 | Stock Option |
2022-08-16 | Goodman Gerald | Buy | 23 333 | Stock Option |
2022-01-21 | Goodman Gerald | Buy | 11 167 | Stock Option |
2021-10-22 | Goodman Gerald | Buy | 87 500 | CS Purchase Warrant |
2023-10-27 | Goodman Gerald | Buy | 49 500 | Stock Option |
INSIDER POWER |
---|
89.52 |
Last 21 transactions |
Buy: 293 666 | Sell: 1 500 500 |
Nutriband Inc. Correlation
10 Most Positive Correlations |
---|
10 Most Negative Correlations |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Nutriband Inc. Financials
Annual | 2022 |
Revenue: | $2.08M |
Gross Profit: | $750 409 (36.08 %) |
EPS: | $-0.570 |
Q3 | 2023 |
Revenue: | $427 841 |
Gross Profit: | $158 921 (37.14 %) |
EPS: | $-0.220 |
Q2 | 2023 |
Revenue: | $655 928 |
Gross Profit: | $299 672 (45.69 %) |
EPS: | $-0.110 |
Q1 | 2023 |
Revenue: | $476 932 |
Gross Profit: | $222 284 (46.61 %) |
EPS: | $-0.130 |
Financial Reports:
No articles found.
Nutriband Inc.
Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. The company's lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. It also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; exenatide for type 2 diabetes; and follicle stimulating hormone for infertility. Nutriband Inc. has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices. The company was incorporated in 2016 and is headquartered in Orlando, Florida.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators